| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| DOI:10.1093/icb/37.4.399 | IVR | 64 mg/kg | 64 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations |
| IVR | 64 mg/kg | 64 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:10220852 | IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:12642156 | IVTH | 0.01 - 20 mg/L | 0.1 - 20 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.01 - 20 mg/L | 0.1 mg/L | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| PMID:16291562 | IVR | 100 mg/kg | 100 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations |
| PMID:18093177 | IVR | 1 mg/kg | 1 mg/kg | Affects spatial learning | Neurological endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:19815845 | IVR | 60 mg/kg | 60 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 60 mg/kg | 60 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:20574914 | IVTH | 0.00000000001 - 0.000004 M | 0.000004 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000000001 - 0.000004 M | 0.000004 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000000001 - 0.000004 M | 0.000004 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000000001 - 0.000004 M | 0.0000004 - 0.000004 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:22517553 | IVR | 32 mg/kg/day | 32 mg/kg/day | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| IVR | 32 mg/kg/day | 32 mg/kg/day | Decrease in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg/day | 32 mg/kg/day | Alters thyroglobulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg/day | 32 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg/day | 32 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg/day | 32 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg/day | 32 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Alters thyroglobulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decrease in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| PMID:22889935 | IVR | 32 mg/kg | 32 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 32 mg/kg | 32 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg | 32 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 32 mg/kg | 32 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| PMID:24754389 | IVTH | 0.0000141 M | 0.0000141 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000004 M | 0.000004 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:26415833 | IVR | 0.00009 - 1.41 mg/kg/day | 0.103 - 0.13 mg/kg/day | Increased thymus gland weights | Immunological endocrine-mediated perturbations |
| IVR | 0.00009 - 1.41 mg/kg/day | 0.15 mg/kg/day | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.00009 - 1.41 mg/kg/day | 0.15 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| PMID:28285191 | IVR | 1 mg/kg/day | 1 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:30414542 | IVTH | 0.001 mg/L | - | No significant effects observed | - |
| IVTH | 0.01 mg/L | - | No significant effects observed | - | |
| IVTH | 0.1 mg/L | - | No significant effects observed | - | |
| IVTH | 0.000001 mg/L | 0.000001 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.000001 mg/L | 0.000001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 mg/L | 0.00001 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.00001 mg/L | 0.00001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | 0.0001 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | 0.0001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:31923581 | IVTH | 0.001 mg/L | - | No significant effects observed | - |
| IVTH | 0.00001 mg/L | 0.00001 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 mg/L | 0.00001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | 0.0001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | 0.0001 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:8516785 | IVR | 64 mg/kg/day | 64 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 64 mg/kg/day | 64 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 64 mg/kg/day | 64 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 64 mg/kg/day | 64 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:8935785 | IVR | 0.05 mg/L | 0.05 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 50 mg/L | 50 mg/L | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/L | 0.5 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Decreased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Decreased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| PMID:9679117 | IVR | 30 mg/kg | 30 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 30 mg/kg | 30 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.